Zhejiang Shouxiangu Pharm Co (603896) — Net Asset Quality Index
Zhejiang Shouxiangu Pharm Co (603896) has a Net Asset Quality Index of 71.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.22 Billion minus total liabilities of CN¥927.41 Million yields net assets of CN¥2.29 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Zhejiang Shouxiangu Pharm Co's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Shouxiangu Pharm Co Net Asset Quality Index Over Time (2012–2025)
This chart shows how Zhejiang Shouxiangu Pharm Co's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 71.2%, representing net assets of CN¥2.29 Billion against total assets of CN¥3.22 Billion CNY. See 603896 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Zhejiang Shouxiangu Pharm Co (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Shouxiangu Pharm Co from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 603896 company net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 68.9% | CN¥2.26 Billion | CN¥3.28 Billion | CN¥1.02 Billion | ▼ -4.4 pp |
| 2024 | 73.3% | CN¥2.29 Billion | CN¥3.13 Billion | CN¥837.17 Million | ▲ +4.9 pp |
| 2023 | 68.4% | CN¥2.17 Billion | CN¥3.17 Billion | CN¥1.00 Billion | ▲ +1.7 pp |
| 2022 | 66.7% | CN¥1.91 Billion | CN¥2.86 Billion | CN¥950.67 Million | ▼ -15.8 pp |
| 2021 | 82.6% | CN¥1.62 Billion | CN¥1.96 Billion | CN¥342.41 Million | ▲ +4.5 pp |
| 2020 | 78.0% | CN¥1.33 Billion | CN¥1.70 Billion | CN¥373.28 Million | ▼ -9.4 pp |
| 2019 | 87.4% | CN¥1.17 Billion | CN¥1.34 Billion | CN¥168.31 Million | ▲ +4.8 pp |
| 2018 | 82.6% | CN¥984.74 Million | CN¥1.19 Billion | CN¥206.79 Million | ▼ -11.2 pp |
| 2017 | 93.9% | CN¥869.75 Million | CN¥926.34 Million | CN¥56.60 Million | ▲ +22.5 pp |
| 2016 | 71.4% | CN¥436.93 Million | CN¥612.10 Million | CN¥175.17 Million | ▲ +10.6 pp |
| 2015 | 60.8% | CN¥368.53 Million | CN¥605.91 Million | CN¥237.38 Million | ▼ -3.2 pp |
| 2014 | 64.0% | CN¥320.56 Million | CN¥500.99 Million | CN¥180.43 Million | ▼ -9.2 pp |
| 2013 | 73.2% | CN¥299.50 Million | CN¥409.35 Million | CN¥109.85 Million | ▲ +22.7 pp |
| 2012 | 50.5% | CN¥138.37 Million | CN¥274.01 Million | CN¥135.64 Million | — |